JP2012532879A - イノシトールトリピロリン酸を使用して多剤耐性を低減する方法 - Google Patents

イノシトールトリピロリン酸を使用して多剤耐性を低減する方法 Download PDF

Info

Publication number
JP2012532879A
JP2012532879A JP2012519703A JP2012519703A JP2012532879A JP 2012532879 A JP2012532879 A JP 2012532879A JP 2012519703 A JP2012519703 A JP 2012519703A JP 2012519703 A JP2012519703 A JP 2012519703A JP 2012532879 A JP2012532879 A JP 2012532879A
Authority
JP
Japan
Prior art keywords
itpp
chemotherapeutic agent
tumor
cisplatin
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012519703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532879A5 (https=
Inventor
ニコラウ，イブ，クラウド
レーン，ジャン−マリー
キーダ，クラウディン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Strasbourg
Original Assignee
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Strasbourg filed Critical Universite de Strasbourg
Publication of JP2012532879A publication Critical patent/JP2012532879A/ja
Publication of JP2012532879A5 publication Critical patent/JP2012532879A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012519703A 2009-07-07 2010-07-07 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法 Pending JP2012532879A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22358309P 2009-07-07 2009-07-07
US61/223,583 2009-07-07
PCT/US2010/041250 WO2011005886A1 (en) 2009-07-07 2010-07-07 Method of reducing multi-drug resistance using inositol tripyrophosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015127462A Division JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Publications (2)

Publication Number Publication Date
JP2012532879A true JP2012532879A (ja) 2012-12-20
JP2012532879A5 JP2012532879A5 (https=) 2013-08-29

Family

ID=43429524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012519703A Pending JP2012532879A (ja) 2009-07-07 2010-07-07 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
JP2015127462A Pending JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015127462A Pending JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Country Status (7)

Country Link
US (3) US20120003327A1 (https=)
EP (1) EP2451459B1 (https=)
JP (2) JP2012532879A (https=)
CN (2) CN103495170A (https=)
MX (1) MX2012000383A (https=)
RU (1) RU2563127C2 (https=)
WO (1) WO2011005886A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
TWI771315B (zh) * 2016-08-26 2022-07-21 奧野哲治 微小奈米化藥劑及其利用
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
MA51276A (fr) * 2017-12-22 2021-04-21 Lo Li Pharma Srl Traitement de la fibrose avec de l'inositol
US20210361680A1 (en) * 2018-05-03 2021-11-25 Normoxys, Inc. Inositol-based immunotherapies
TWI686210B (zh) 2018-06-01 2020-03-01 國立清華大學 用以誘導病變組織血管正常化的套組及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10287657A (ja) * 1997-04-08 1998-10-27 Pola Chem Ind Inc 放射線増感剤の製造方法
JP2003509413A (ja) * 1999-09-13 2003-03-11 良尋 高井 新規ニトロイミダゾール誘導体及びこれを含む画像診断薬
JP2009522355A (ja) * 2006-01-06 2009-06-11 オキシプラス インコーポレイテッド 腫瘍および疾患の治療におけるイノシトール−トリピロリン酸の使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
US6632797B2 (en) * 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US7084115B2 (en) * 2002-04-29 2006-08-01 Oxyplus, Inc. Inositol pyrophosphates, and methods of use thereof
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
PL1863495T3 (pl) * 2005-03-18 2015-06-30 Normoxys Inc Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10287657A (ja) * 1997-04-08 1998-10-27 Pola Chem Ind Inc 放射線増感剤の製造方法
JP2003509413A (ja) * 1999-09-13 2003-03-11 良尋 高井 新規ニトロイミダゾール誘導体及びこれを含む画像診断薬
JP2009522355A (ja) * 2006-01-06 2009-06-11 オキシプラス インコーポレイテッド 腫瘍および疾患の治療におけるイノシトール−トリピロリン酸の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014030563; Ｐｒｏｃ．　Ｎａｔｌ．　Ａｃａｄ．　Ｓｃｉ． Ｖｏｌ．１０３　Ｎｏ．４２, 2006, ｐｐ．１５５７６-１５５８１ *
JPN6014030566; Ａｎｔｉｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．２５, 2005, ｐｐ．３４１３-３４１８ *

Also Published As

Publication number Publication date
US20120003327A1 (en) 2012-01-05
EP2451459A1 (en) 2012-05-16
RU2012104022A (ru) 2013-08-20
JP2015166393A (ja) 2015-09-24
WO2011005886A1 (en) 2011-01-13
RU2563127C2 (ru) 2015-09-20
CN102573853A (zh) 2012-07-11
MX2012000383A (es) 2012-06-01
EP2451459A4 (en) 2013-12-11
US20160235771A1 (en) 2016-08-18
EP2451459B1 (en) 2017-11-22
CN103495170A (zh) 2014-01-08
US20140199261A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
JP2015166393A (ja) イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
Li et al. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy
Sun et al. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer
WO2021098679A1 (zh) Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途
Ling et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
US20140038901A1 (en) Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
Feng et al. A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3
CA2841217A1 (en) Novel sulfonamide compounds for inhibition of metastatic tumor growth
Gao et al. Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer
Li et al. Tumor-penetrating iRGD facilitates penetration of poly (floxuridine-ketal)-based nanomedicine for enhanced pancreatic cancer therapy
KR20150095809A (ko) 암 치료용 조성물 및 방법
Ding et al. “Sweet tooth”-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy
AU2012250650A1 (en) Methods for treating prostate cancer
Li et al. Biological activities of siRNA-loaded lanthanum phosphate nanoparticles on colorectal cancer
Fang et al. ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy
CN116474114A (zh) 一种载分子靶向药物聚合物囊泡及其制备方法与应用
KR102569052B1 (ko) 암의 치료를 위한 약제학적 조합물
Liu et al. Nano-cannabidiol to orchestrate inflammatory homeostasis via macrophage metabolism reprogramming for targeted treatment atherosclerosis
US12478658B2 (en) Enhanced efficacy of combination of gemcitabine and phosphatidylserine-targeted nanovesicles against pancreatic cancer
KR102939983B1 (ko) 1,1-다이에톡시에떼인을 유효성분으로 포함하는 항암제
Lai et al. Intravesical cascade delivery of active monoterpene coumarin for bladder cancer therapy
Wang et al. Peptide modified lipid nanoparticles Co-Delivering IL-12 mRNA and PD-L1 siRNA for glioblastoma immunotherapy
JP2025166160A (ja) Ｆ１６イソインドール小分子を使用する固形腫瘍の治療のための方法及び組成物
Maksoudian et al. The exploration of inorganic nanoparticle delivery to solid tumors and their therapeutic potential
JP2016539954A (ja) 中皮腫の処置で使用するためのエストロゲン受容体ベータアゴニスト

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150804

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150902

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160914